The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
A retrospective study of 250 adults found most safely used GLP-1 receptor agonists and dermatologic biologics together for 19 months. Only 19-39% of discontinuations linked to side effects, matching known individual drug profiles. Clinicians gain reassurance for patients with metabolic and immunologic needs.
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
Alisha Trafford called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain led to hospitalizations for pancreatitis and pancreatic necrosis, linked by doctors to the drug. She warns others to monitor symptoms closely.
GLP-1 receptor agonists excel in weight management and glucose control, but their effects on women's reproductive health demand attention. These drugs can restore ovulation in obese women with insulin resistance, yet they risk unplanned pregnancies and are unsafe during gestation. Consult experts before use.
GLP-1 weight loss drugs like Ozempic may trim airline fuel bills alongside waistlines. A Jefferies report estimates $580M annual savings for top US carriers from lighter passengers. Discover the science and implications.
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
